Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Dec 3;71(9):e439-e448.
doi: 10.1093/cid/ciaa163.

Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study

Karina A Top  1 , Wendy Vaudry  2 , Shaun K Morris  3 , Anne Pham-Huy  4 , Jeffrey M Pernica  5 , Bruce Tapiéro  6 , Soren Gantt  7 , Victoria E Price  8 , S Rod Rassekh  9 , Lillian Sung  3 , Athena McConnell  10 , Earl Rubin  11 , Rupesh Chawla  12 , Scott A Halperin  13
Affiliations
Multicenter Study

Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study

Karina A Top et al. Clin Infect Dis. .

Abstract

Background: There is no uniform guideline for postchemotherapy vaccination of children with acute lymphoblastic leukemia (ALL). We evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vaccinated children treated for ALL.

Methods: This was a multicenter trial of children with ALL enrolled 4-12 months postchemotherapy completion. Exclusion criteria included: infant ALL, relapsed ALL, and stem cell transplant recipients. Immunocompetent children were recruited as controls. Postchemotherapy participants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later. Serology was measured at baseline, 2 and 12 months postvaccination. Adverse events were captured via surveys.

Results: At enrollment, postchemotherapy participants (n = 74) were less likely than controls (n = 78) to be age-appropriately immunized with DTaP (41% vs 89%, P < .001) and PCV (59% vs 79%, P = .008). Geometric mean concentrations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemotherapy participants than controls after adjusting for previous vaccine doses (P < .001). Two months postvaccination, GMCs to TT, PT, and PCV serotypes increased from baseline (P < .001 for all antigens) and remained elevated at 12 months postvaccination. Antibody levels to PPV23 serotypes also increased postvaccination (P < .001). No serious adverse events were reported.

Conclusions: Children treated for ALL had lower antibody levels than controls against pneumococcal serotypes, tetanus, pertussis, and varicella despite previous vaccination. Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well tolerated. Children with ALL would benefit from systematic revaccination postchemotherapy.

Clinical trials registration: NCT02447718.

Keywords: chemotherapy; immunization; immunosuppression; vaccination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participant flow chart. Abbreviations: DTaP-IPV-Hib, diphtheria-tetanus-acellular pertussis-inactivated polio-Haemophilus influenzae type b vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine.
See this image and copyright information in PMC

References

    1. Möricke A, Reiter A, Zimmermann M, et al. ; German-Austrian-Swiss ALL-BFM Study Group Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111:4477–89. - PubMed
    1. Rubin LG, Levin MJ, Ljungman P, et al. ; Infectious Diseases Society of America 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44–100. - PubMed
    1. Silverman LB. Acute lymphoblastic leukemia. In: Orkin SH, Fisher DE, Look T, Lux SE, Ginsburg D, Nathan DG. Oncology of Infancy and Childhood. Philadelphia, PA: Saunders Elsevier, Inc., 2009:295–330.
    1. Pelland-Marcotte M-C, Pole JD, Hwee J, et al. . Long-term risk of infections after treatment of childhood leukemia: a population-based cohort study using administrative health data. J Clin Oncol 2019; 37:2651–60. - PubMed
    1. Meisel R, Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, von Kries R. Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol 2007; 137:457–60. - PubMed

Publication types

Associated data

Grants and funding